➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Moodys
Boehringer Ingelheim
Merck
AstraZeneca

Last Updated: September 22, 2020

DrugPatentWatch Database Preview

Patent: 7,867,727

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,867,727
Title:Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration
Abstract: Disclosed are screening methods for determining a human subject\'s propensity to develop a vascular disorder and/or age-related macular degeneration (AMD), therapeutic or prophylactic compounds for treating disease or inhibiting its development, and methods of treating patients to alleviate symptoms of the disease, prevent or delay its onset, or inhibit its progression. The inventions are based on the discovery that persons with a genome having a deletion of the CFHR-1 and/or CFHR-3 gene, which normally lie on human chromosome 1 between DNA encoding CFH and CFHR-4, are at reduced risk of developing AMD, and elevated risk of developing vascular disease such as aneurysm.
Inventor(s): Hageman; Gregory S. (Coralville, IA)
Assignee: University of Iowa Research Foundation (Iowa City, IA)
Application Number:11/894,667
Patent Claims:see list of patent claims

Details for Patent 7,867,727

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial University of Iowa Research Foundation (Iowa City, IA) 2026-07-13 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial University of Iowa Research Foundation (Iowa City, IA) 2026-07-13 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial University of Iowa Research Foundation (Iowa City, IA) 2026-07-13 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Harvard Business School
Express Scripts
McKesson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.